Skip to main content
Premium Trial:

Request an Annual Quote

Mirna Receives Notices of Allowance for Patents Related to Tumor-Suppressor miRNAs


Mirna Therapeutics said this week that it has received notices of allowance for US patent application claims related to the therapeutic use of several tumor-suppressor microRNAs.

“The allowed claims include methods for reducing cancer cell proliferation by introducing mimics of miR-192 or miR-215 into cancer cells,” the company said. “Additional claims are directed to the use of miR-192 and miR-215 for specifically reducing proliferation of breast, cervical, colon, or skin cancer cells, and to methods for reducing cancer cell viability and inducing apoptosis by introducing miR-192 mimics into lung cancer cells.”

Mirna also said that it has received notices of allowance from the US Patent and Trademark Office for claims related to administering miRNA combinations to inhibit prostate and liver cancer cell proliferation.

“The allowed claims describe the use of miR-124 in combination with miR-34a, let-7b, let-7c, or let-7g for inhibiting cancer cell proliferation,” it said. Additional claims are directed to uses of the miRNA combinations with specific liver and prostate carcinoma types and to specific pharmaceutical formulations of the miRNA combinations.”

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.